Although the prognosis of Ph‐positive ALL patients treated with standard chemotherapy alone was previously very poor, the development of tyrosine kinase inhibitors (TKIs) specific for BCR::ABL1 oncoprotein was a great innovation21, 22 that dramatically improved therapeutic outcomes in Ph‐positive ALL patients through the introduction of TKI‐combined chemotherapy.23, 24, 25. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.